Drug Pricing

  • A photo of President Trump in front of a TrumpRx sign
    Image attribution tooltip
    Nathan Howard via Getty Images
    Image attribution tooltip
    Trump administration

    White House’s online service for drug sales debuts with limited impact on prices

    Select products from Pfizer, Eli Lilly and others will be sold at a discount, although the lower costs won’t be felt by many Americans whose medications are covered by insurance.

    By • Feb. 6, 2026
  • The Federal Trade Commission entrance is seen in 2025 in Washington, DC.
    Image attribution tooltip
    Leigh Vogel via Getty Images
    Image attribution tooltip

    Express Scripts reaches ‘landmark’ settlement with FTC in insulin suit

    The agreement announced Wednesday includes sweeping changes to the Cigna PBM’s business practices, including no longer preferring expensive drugs over cheaper equivalents on standard formularies and reshoring its controversial rebate aggregator.

    By Rebecca Pifer Parduhn • Updated Feb. 4, 2026
  • Explore the Trendline➔
    Image attribution tooltip
    Elizabeth Regan/BioPharma Dive
    Image attribution tooltip
    Trendline

    Drug pricing

    President Trump’s efforts to install a most-favored nation pricing policy present new risks for an industry already adjusting to Medicare price negotiations.

    By BioPharma Dive staff
  • Mike Doustdar
    Image attribution tooltip
    Permission granted by Novo Nordisk
    Image attribution tooltip

    Novo shares tumble by double digits on grim sales outlook

    In contrast to Lilly’s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13% decline in 2026 profits. 

    By • Feb. 4, 2026
  • A piece of paper with the word "Medicare" emblazoned on a blue background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trump administration

    Drugs for cancer, arthritis and HIV on Medicare’s list for 2028 price cuts

    Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — draw very limited revenue from Medicare, an analyst pointed out.

    By • Jan. 28, 2026
  • The Federal Trade Commission entrance is seen in 2025 in Washington, DC.
    Image attribution tooltip
    Leigh Vogel via Getty Images
    Image attribution tooltip

    Express Scripts considering settlement in FTC insulin price lawsuit

    The antitrust agency paused its lawsuit against the pharmacy benefit manager while the two discuss a proposed consent agreement.

    By Emily Olsen • Jan. 26, 2026
  • The top of the U.S. Capitol Building's dome is pictured on a cloudy day.
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Congress eyes tackling healthcare consolidation

    “I think there’s common ground here,” one Republican congressman said Wednesday during a House Budget Committee hearing. Squaring up against healthcare monopolies would be a major pivot for the GOP.

    By Rebecca Pifer Parduhn • Jan. 23, 2026
  • A person speaking.
    Image attribution tooltip
    Samuel Corum via Getty Images
    Image attribution tooltip

    Trump unveils healthcare affordability plan

    The “Great Healthcare Plan” is vague, but would send money directly to ACA enrollees and entrench the pricing deals the administration has cut with more than a dozen drugmakers.

    By Rebecca Pifer Parduhn • Jan. 15, 2026
  • The AbbVie logo is prominently displayed on the facade of a sleek, contemporary building surrounded by a clear blue sky.
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Trump administration

    AbbVie pledges $100B to US production in drug pricing deal with Trump

    As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on details as well as its potential financial impact.

    By • Jan. 13, 2026
  • A photo of President Trump at the White House in front of several pharmaceutical executives
    Image attribution tooltip
    Alex Wong / Staff via Getty Images
    Image attribution tooltip
    Trump administration

    Biopharma climbs higher as 9 drugmakers ink ‘pandering’ drug price deals with Trump

    Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive other benefits from the agreements.

    By Kristin Jensen • Dec. 22, 2025
  • An elderly gentleman walks past a hospital sign on September 26, 2007 in London, England. In a report to be released September 27, 2007 the Healthcare Commission outlines care by the NHS Trust should provide further dignity in care to the elderly.
    Image attribution tooltip
    Cate Gillon via Getty Images
    Image attribution tooltip

    UK agrees to boost drug prices to dodge US pharma tariffs

    A deal announced Monday will see the U.K. temporarily sidestep levies on Britain-originated drugs by loosening rules that restrain prices for new medicines.

    By • Dec. 1, 2025
  • Two prescription drug cartons stand side by side on a counter, each bearing the word Wegovy.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    CMS sets 2027 Medicare prices for Wegovy, Trelegy and 13 other drugs

    The second round of negotiations cuts spending an aggregate 44% over 2024 list prices as the federal government extends restraints over more medicines.

    By • Nov. 26, 2025
  • Trump RFK EO
    Image attribution tooltip
    Andrew Harnik/ via Getty Images
    Image attribution tooltip

    CMS to launch model to lower Medicaid drug spending

    Under the model, set to start next year, the CMS will negotiate lower prices for Medicaid programs linked to those paid in select other countries.

    By Emily Olsen • Nov. 7, 2025
  • David Ricks, CEO of Eli Lilly, speaks alongside U.S. President Donald Trump, administration officials and fellow pharmaceutical executives on November 06, 2025 in Washington, DC.
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip
    Trump administration

    Novo, Lilly cut deal with Trump to lower prices of obesity drugs

    The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of pill versions, once approved, for $149 monthly.

    By • Updated Nov. 7, 2025
  • Medicine pill on 100 dollar banknote background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    HRSA approves 340B rebate models to hospitals’ chagrin

    Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara and Novo Nordisk’s Novolog.

    By Rebecca Pifer Parduhn • Oct. 31, 2025
  • man in a dark blue suit speaks in the oval office
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    FDA, aiming to lower drug costs, moves to speed approval of biosimilars

    The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help developers bring them to market more quickly and cheaply. 

    By • Oct. 29, 2025
  • Glucagon-like peptide 1 (GLP1, 7-36) molecule The glucagon like peptide-1 receptor has a strong effect on the management of type 2 diabetes mellitus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly aligns with Walmart in bid to broaden access to discounted Zepbound

    The deal, which enables patients to pick up orders placed through Lilly’s online channel at Walmart pharmacies, is the latest move by the company to expand its direct-to-consumer services. 

    By • Oct. 29, 2025
  • Close-up view of the Novo Nordisk logo mounted on the exterior wall of a building. The logo features a stylized blue Apis bull with a sun disk above its head, symbolizing the company's identity. The background shows a tan brick wall and part of a leafless tree in the foreground under a clear blue sky."
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Novo’s main shareholder pushes out more than half of company’s board

    The Novo Foundation chair said the current board of the Wegovy maker, which is already dealing with layoffs and a CEO change, was too slow to react to obesity market shifts.

    By • Oct. 21, 2025
  • Hospital Hallway with Doctors, Nurses and Specialists in Hospital. F
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    California passes laws targeting PBMs, private equity

    Gov. Gavin Newsom signed an array of healthcare bills into law last week that crack down on pharmacy benefit managers and beef up the review process for deals involving private equity firms.

    By Susanna Vogel • Oct. 16, 2025
  • A photo of a man speaking
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip
    Trump administration

    Trump, Pfizer drug pricing deal short on details, possible impact

    A pact to offer “most favored nation” prices to state Medicaid programs and via direct-to-consumer channels doesn’t affect those on commercial insurance or who won’t pay out of pocket.

    By • Sept. 30, 2025
  • U.S. President Donald Trump shakes hands with President of the European Commission Ursula von der Leyen as he announces a trade deal with the EU at Trump Turnberry golf club on July 27, 2025 .
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Pharma reshoring

    Key exemptions could limit impact of Trump’s pharmaceutical tariffs

    Carve-outs for generics, European exports and companies onshoring drug production will likely shield most branded drugs from the 100% levies Trump announced Thursday.

    By • Sept. 26, 2025
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Trump administration

    Lilly says it will raise drug prices in Europe, responding to Trump threats

    As the Trump administration works to implement a “most-favored nation” policy, Lilly said it’s “rebalancing” prices to “align” costs across different countries.

    By • Aug. 14, 2025
  • Customer, service and medicine prescription at pharmacy with help from healthcare expert at store counter.
    Image attribution tooltip

    shutterstock.com/PeopleImages.com - Yuri A

    Image attribution tooltip
    Sponsored by GoodRx

    Regulatory uncertainty and access challenges changing go-to-market models, DTC, and DTP

    DTC isn’t converting to Rxs at the pharmacy. Learn how access may be key to your brand’s success.

    Aug. 11, 2025
  • Medicine pill on 100 dollar banknote background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Drugmakers score policy win in fight against 340B

    A new pilot program from HHS will test alterations to the contentious 340B pricing program by swapping traditional upfront drug discounts for rebates.

    By Amy Baxter • Aug. 4, 2025
  • A stethoscope rests on a pile of $100 bills.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Trump administration to pilot 340B rebate model next year

    The pilot departs from the current model, which gives hospitals upfront discounts for some drugs. Hospitals say 340B is a lifeline, while drugmakers claim hospitals have abused the program.

    By Susanna Vogel • Aug. 1, 2025
  • The White House in Washington, D.C.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Trump redoubles threats in attempt to strongarm drugmakers on prices

    The White House set a 60-day deadline for drugmakers to agree on “most favored nation” prices for Medicaid as well as for newly launched drugs.

    By • July 31, 2025